Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.66 |
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.60 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.51 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.50 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.50 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30553888 | 0.98 | MAPK1 (0.68) | MAPK1CA1CA2CA9KDM4E | |
| SCHEMBL2459763 | 0.98 | MAPK1 (0.68) | MAPK1CA1CA2CA9KDM4E | |
| SCHEMBL4108644 | 0.96 | MAPK1 (0.66) | MAPK1CA1CA2CA9KDM4E | |
| Fluoride SCHEMBL27733510 | 0.96 | MAPK1 (0.66) | MAPK1CA1CA2CA9KDM4E | |
| SCHEMBL31440873 | 0.84 | KDM4E (0.56) | MAPK1CA1CA2CA9KDM4E | |
| SCHEMBL28348888 | 0.83 | KDM4E (0.54) | MAPK1CA1CA2CA9KDM4E | |
| SCHEMBL27592567 | 0.81 | MAPK1 (0.70) | MAPK1CA1CA2CA9KDM4E | |
| SCHEMBL7180056 | 0.81 | MAPK1 (0.70) | MAPK1CA1CA2CA9KDM4E | |
| SCHEMBL51046 | 0.79 | MAPK1 (0.68) | MAPK1CA1CA2CA9KDM4E | |
| SCHEMBL50688 | 0.79 | MAPK1 (1.00) | MAPK1CA1CA2CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110317137-A | 9,10- anthraquinone analog compound or its pharmaceutically acceptable salt and its medicinal usage | 复旦大学 | 2019-10-11 | — | — | CN | disclosed |
| CN-108610301-A | A kind of chiral fragrant miscellaneous amine derivant and its synthetic method and application | 中山大学 | 2018-10-02 | — | — | CN | disclosed |
| CN-106008322-B | sulfonamide derivatives as BC L-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE 公司 | 2018-09-04 | — | — | CN | disclosed |
| CN-104822672-B | The purposes of therapeutic compound and composition as well as PKM2 conditioning agents | 安吉奥斯医药品有限公司 | 2018-08-28 | — | — | CN | disclosed |
| CN-108191746-A | A kind of novel hydroxyl pyridine compounds and preparation method and application | 暨南大学 | 2018-06-22 | — | — | CN | disclosed |
| CN-108101948-A | Macrocyclic compound and its making and use method | 瑞伯-X医药品有限公司 | 2018-06-01 | — | — | CN | disclosed |
| CN-104817498-B | Therapeutic compound and composition | 安吉奥斯医药品有限公司 | 2018-06-01 | — | — | CN | disclosed |
| CN-107954906-A | A kind of synthetic method of arylsulfonyl tertiary amine compounds | 西北师范大学 | 2018-04-24 | — | — | CN | disclosed |
| CN-105272888-B | Double aryl alkene alkane acid compounds and its production and use | 中国科学院上海药物研究所 | 2018-03-27 | — | — | CN | disclosed |
| CN-104230766-B | Carboxamides derivatives, intermediate, preparation method, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2017-06-23 | — | — | CN | disclosed |
| US-6114532-A | ANTICOAGULANT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-05 | — | — | US | disclosed |
| CN-1215990-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-05-05 | — | — | CN | disclosed |
| EP-0729293-A1 | Selective metallization process | Calabrese, Gary S. (US) | 1996-08-28 | — | — | EP | disclosed |
| US-5510216-A | Selective metallization process | SHIPLEY COMPANY INC. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5500315-A | AN ARTICLE COMPRISING AN IMAGE PATTERN ON A SUBSTRATE | ROHM & HAAS COMPANY (US) | 1996-03-19 | — | — | US | disclosed |
| US-5468597-A | Selective metallization process | SHIPLEY COMPANY, L.L.C. (US) | 1995-11-21 | — | — | US | disclosed |
| US-5391556-A | Thrombin inhibitors | KARL THOMAE GMBH (DE) | 1995-02-21 | — | — | US | disclosed |
| US-5389496-A | Using chemical groups capable of ligating with an electroless metallization catalyst, including use of ligating groups chemically bound to the substrate | ROHM AND HAAS COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| US-5235072-A | 2-OXABICYCLO(2,2,1)HEPTANE DERIVATIVES AND PHARMACEUTICAL | SCHERING AKTIENGSELLSCHAFT (DE) | 1993-08-10 | — | — | US | disclosed |
| EP-0510711-A2 | Processes and compositions for electroless metallization | Calvert, Jeffrey M. (US) | 1992-10-28 | — | — | EP | disclosed |